Key Findings From Recent Trials

Basic Zydena Information

• INN (International Nonproprietary Name): Udenafil
• Brand Names Available In Canada (English): Zydena, Zidena, Udenafilo — no approvals or branded packaging reported for Canada, the U.S., or the EU as of July 2025
• ATC Code: G04BE10
• Forms & Dosages: Tablet strengths 100 mg (typical blister 4, 8, or 10 tabs) and 200 mg (typical blister 4 or 8 tabs); marketed in Korea, CIS and select Asian markets
• Manufacturers In Canada (English): Originator manufacturer is Dong‑A Pharmaceutical (Seoul, South Korea); no Canadian manufacturers reported as of July 2025
• Registration Status In Canada (English): Not approved by Health Canada; no Drug Identification Number (DIN) as of July 2025
• OTC / Rx Classification: Prescription only (Rx) in all registered countries; not registered for sale in Canada without prescription and regulatory authorisation

Major 2022–2025 Canadian & Global Studies

Patients and prescribers ask whether Zydena is backed by modern trials in Canada and globally.

Between 2022 and 2025, peer‑reviewed trials and post‑marketing surveillance for phosphodiesterase type‑5 inhibitors focused on comparative duration and tolerability.

Most udenafil data remain concentrated in South Korea and CIS registries rather than Canadian cohorts.

International phase IV and observational cohorts from Korea, the Philippines and Russia reaffirmed the labelled on‑demand profile of an initial 100 mg dose with a single‑dose maximum of 200 mg per 24 hours.

Those studies reported an efficacy window commonly between six and 12 hours, which is longer than sildenafil’s typical duration in many reports.

No Health Canada‑led trials or DIN listings for Zydena/Zidena were registered as of July 2025, limiting direct Canadian clinical evidence.

Main Outcomes

Across the regional studies, erectile function scores improved from baseline in treated patients.

Onset of effect was typically between 30 and 60 minutes after oral dosing in on‑demand regimens.

Responder rates were comparable to mid‑range PDE5 inhibitors in those cohorts.

Safety Observations

Reported adverse events were consistent with PDE5 class effects: headache, flushing, nasal congestion, dyspepsia and myalgia.

Transient visual changes were reported rarely and less frequently than with sildenafil in originator summaries.

No new Canadian safety signals were identified because domestic use data are absent.

Clinical Mechanism Of Action

Layman’s Explanation

People often want a plain answer: how does udenafil help with erections?

Udenafil is a PDE5 inhibitor that boosts the nitric oxide to cGMP signalling pathway in penile tissue during sexual stimulation.

That amplification improves blood flow into the corpora cavernosa so a natural erection can develop when sexually aroused.

Take it 30–60 minutes before activity for on‑demand use, and the drug lowers PDE5 activity to help restore normal erectile physiology.

Scientific Breakdown

At the molecular level, udenafil selectively inhibits phosphodiesterase type‑5, increasing intracellular cyclic guanosine monophosphate (cGMP).

Higher cGMP relaxes smooth muscle in the corpora cavernosa, allowing increased arterial inflow and restricted venous outflow necessary for erection.

These pharmacodynamic effects are the shared mechanism across PDE5 inhibitors such as sildenafil, tadalafil and vardenafil.

Pharmacokinetics (Short)

Market tablets (Zydena in 100 mg and 200 mg strengths) show moderate onset and an extended duration up to roughly 12 hours in trials from Korea.

Hepatic metabolism predominates, so dose adjustment is advised in moderate to severe hepatic impairment and use is not recommended in severe cases.

Clinical implication: udenafil demonstrates class effects similar to sildenafil and tadalafil but often with a slightly longer effective window.

Avoid nitrates because the combination risks profound hypotension due to additive vasodilatory effects.

Scope Of Approved & Off‑Label Use

Health Canada Approvals (DIN‑Based)

Patients frequently ask whether Zydena is on the Canadian market.

As of July 2025 there is no Health Canada approval and no Drug Identification Number (DIN) for Zydena or udenafil.

Market authorisations exist in South Korea (Dong‑A), Russia/CIS and select Asia/Philippines markets but not in Canada.

Notable Off‑Label Trends In Canadian Practice

Off‑label use of udenafil in Canada is minimal and pharmacovigilance data are sparse.

Some Canadians report sourcing udenafil through international e‑pharmacies where products are labelled Zydena, Zidena or Udenafilo.

Clinicians caution against unverified imports because there is no DIN, lot integrity can be uncertain, and bilingual labelling required by Canadian law is missing.

Provincial drug benefit plans such as ODB, BC PharmaCare and RAMQ will not reimburse non‑DIN products.

Community pharmacies including Shoppers, Rexall, London Drugs and Jean Coutu must refuse dispensing non‑approved imports as part of standard practice.

Dosage Strategy

General Dosing Per Health Canada Monographs

There is no Canadian monograph for udenafil because a DIN has not been issued.

Relying on originator labelling and published dosing, the initial on‑demand dose is 100 mg taken 30–60 minutes before sexual activity.

The maximum single dose is 200 mg and dosing frequency should not exceed once per 24 hours.

Condition‑Specific Dosing Adjustments

For elderly patients, start at 100 mg and titrate as tolerated.

In renal impairment, mild to moderate caution is advised and starting at the lowest feasible dose is recommended; severe renal impairment is not recommended due to lack of data.

Hepatic impairment requires caution in mild disease and avoidance in moderate to severe cases.

Udenafil is not indicated in individuals under 18 years of age.

Practical dispensing guidance for Canadian pharmacists: when a patient presents with internationally sourced Zydena, document the product source, counsel on risks including lack of DIN and possible counterfeit tablets, and advise discussion with the prescriber before use.

Safety Protocols

Contraindications (Canadian Advisories)

Apply standard PDE5 safety checks when advising patients about imported Zydena.

Absolute contraindications from originator/regional labelling include hypersensitivity to udenafil, concurrent use of nitrates, severe hepatic or renal impairment, and unstable cardiovascular disease such as recent myocardial infarction or stroke.

Canadian clinicians should treat imported Zydena as non‑approved and apply the same safety screening as for any PDE5 inhibitor.

Adverse Effects (Post‑Market Reports)

Regional post‑marketing data list headache, flushing, nasal congestion, dyspepsia, back pain and myalgia as the most common side effects.

Transient visual disturbances appear less frequent than with sildenafil according to originator summaries.

Priapism remains a rare but serious risk and requires immediate emergency care.

Overdose management is supportive because there is no specific antidote.

Risk mitigation steps include screening for nitrates and nitrites, alpha‑blocker use and uncontrolled hypotension, and documenting informed consent for off‑label or imported use.

Interaction Mapping

Food Interactions Common In Canadian Diet

High‑fat meals may delay onset of udenafil, similar to other PDE5 inhibitors.

Large evening meals typical in Canadian dining can slow absorption, so advise patients to take the tablet 30–60 minutes before activity and avoid heavy meals if a faster onset is desired.

Drug Combinations Flagged By Health Canada

Although Health Canada does not have an udenafil label, known class interactions apply.

Concurrent nitrates are an absolute contraindication because of the risk of severe hypotension.

Caution is required with alpha‑blockers due to orthostatic hypotension potential, and with strong CYP3A4 inhibitors—like ketoconazole or some HIV protease inhibitors—which can raise udenafil exposure and require dose adjustment or avoidance.

CYP3A4 inducers may reduce udenafil efficacy.

Pharmacy action: always check a full medication history including over‑the‑counter nitroglycerin sprays and topical nitrates, and notify the prescriber if a patient is importing Zydena.

Patient Experience Analysis

Canadian Survey Data

There are no large Canadian surveys for udenafil given the lack of approval and limited domestic availability.

International cohorts report patient satisfaction often linked to the sustained duration of effect of six to 12 hours and predictable on‑demand efficacy.

Discontinuation typically stems from adverse effects or lack of perceived benefit compared with familiar brands such as sildenafil or tadalafil.

Forum & Community Pharmacy Trends

Online forums and e‑pharmacy reviews from Korean and CIS sellers show mixed feedback: some users praise Zydena for longer performance while others note delayed onset with heavy meals or headaches.

Community pharmacists in Canada report sporadic patient queries about importing Zydena and emphasise legal, safety and reimbursement limitations.

Pharmacists typically refer patients to their prescriber and suggest trying a DIN‑approved alternative first.

Patient counselling tip: set realistic expectations about onset and duration, explain likely adverse effects, and encourage reporting of side effects to MedEffect Canada if imported use occurs.

Distribution & Pricing Landscape

National Pharmacy Chains (Shoppers, Rexall, Jean Coutu, London Drugs)

Major Canadian chains stock DIN‑approved PDE5 drugs including sildenafil, tadalafil, vardenafil and avanafil.

Those chains do not stock Zydena because it lacks a DIN in Canada.

Patients seeking udenafil commonly report international online purchases rather than in‑store dispensing.

Online Pharmacy Availability & Provincial Restrictions

Zydena is available via international e‑pharmacies and sometimes through unregulated marketplaces, most often shipped from Korea or CIS suppliers.

Provincial drug plans—Ontario Drug Benefit (ODB), BC PharmaCare and RAMQ—require a DIN for reimbursement and will not cover imported udenafil.

Pharmacies must follow Canada Border Services and Health Canada importation rules when advising patients.

In our online pharmacy, zydena is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Cross‑Border US Comparisons

Udenafil is not FDA‑approved in the United States as of July 2025, and U.S. availability is limited.

Price comparisons can be misleading because cheap online packages carry a counterfeit or variable potency risk.

Canadian patients should consider tariffs, shipping delays and safety risk against domestic generics such as sildenafil or tadalafil, which are widely available and often less expensive after insurance.

Alternative Options

Comparison Table Of DIN‑Approved Alternatives

Canadian DIN‑approved PDE5 options include sildenafil (Viagra and generics), tadalafil (Cialis and generics), vardenafil (Levitra) and avanafil (Stendra).

Sildenafil typically has onset around 30–60 minutes and duration about four to six hours.

Tadalafil offers a longer duration, up to 36 hours in many patients, and avanafil is known for a faster onset.

Udenafil is positioned between sildenafil and tadalafil in duration per international reports, but it lacks Canadian approval and a DIN.

Pros And Cons Checklist

• Pros Of Approved Alternatives: DIN‑regulated manufacturing, availability at Shoppers, Rexall, Jean Coutu and London Drugs, established safety data and potential reimbursement under some plans.
• Cons: Individual variability in onset and duration; some patients may prefer udenafil’s reported intermediate duration but must weigh regulatory and safety trade‑offs.

Recommendation: try a trial of a DIN‑approved PDE5 with documented dosing adjustments before considering imports.

Regulatory Status

Health Canada Approval Process

Health Canada requires a New Drug Submission (NDS) demonstrating quality, safety and efficacy before issuing a Drug Identification Number (DIN).

As of July 2025, udenafil (Zydena/Zidena/Udenafilo) has no NDS approval and no DIN in Canada.

The originator Dong‑A received Korean MFDS approval in 2005 for Zydena but has not secured Canadian authorisation.

DIN And Bilingual Labelling Rules

Any product sold in Canada must meet DIN requirements and carry bilingual English/French labelling when marketed domestically.

Pharmacies cannot legally add non‑DIN prescription products to regular inventory, although patients may import limited personal supplies under specific rules.

Pharmacists should document counselling when patients present imported products and direct adverse event reports to MedEffect Canada.

Consolidated FAQ

Q1: Is Zydena (udenafil) approved in Canada?

No. As of July 2025, Zydena is not approved by Health Canada and has no DIN.

Q2: Can I import Zydena for personal use?

Limited personal importation is possible, but it is not recommended without prescriber or pharmacist oversight because of safety, authenticity and labelling concerns; provincial plans will not cover it.

Q3: How does udenafil compare to Viagra or Cialis?

Udenafil’s duration is generally longer than sildenafil but shorter than tadalafil in regional studies, with an onset of roughly 30–60 minutes; no Canadian head‑to‑head randomized controlled trials are available.

Q4: Are side effects different?

Side effects are class‑related—headache, flushing and nasal congestion are common—and transient visual changes are reported less frequently than with sildenafil in originator summaries.

Q5: What should I tell my pharmacist?

Disclose all medications especially nitrates, the source of any imported product and any cardiac history; the pharmacist will advise on risks and reporting options.

Visual Guide

This section describes three practical visuals to help patients and pharmacists quickly assess dosing, coverage and purchase routes.

Visual 1: Dosage Flowchart — Start 100 mg; assess response and tolerability; consider escalation to 200 mg single dose if tolerated; include renal and hepatic adjustment boxes and contraindication icons for nitrates and severe cardiovascular disease.

Visual 2: Provincial Coverage Map — Colour‑coded provinces showing that non‑DIN products have no public coverage; overlay ODB, BC PharmaCare and RAMQ policies and show major pharmacy network availability for DIN PDE5s.

Visual 3: Purchase Channels Decision Tree — Guide patients from common myths (OTC beliefs) to the DIN‑approved pharmacy path and highlight international e‑pharmacy risks such as counterfeit products, missing bilingual labelling and shipping delays.

Design note: each visual should include INN udenafil and brand examples Zydena/Zidena/Udenafilo and a clear banner: "Not Health Canada Approved (July 2025)".

Storage & Transport

Canadian Household Guidelines

Store Zydena or any udenafil tablet below 25°C (77°F) in the original blister to protect from moisture and light.

Avoid storing medicines in bathrooms or glove compartments where heat and humidity vary.

Use a cool, dry medicine cabinet away from direct sunlight.

Cold‑Chain Storage Where Applicable

Udenafil tablets do not require cold‑chain transport but should be kept in temperature‑stable packaging during shipping.

For cross‑border mailings advise tracked, tamper‑evident packaging to minimise exposure to extremes during long transit routes across Canada.

If patients present imported Zydena, inspect packaging for intact blister seals, lot numbers and expiry dates; note that missing bilingual labelling and a DIN remain regulatory concerns even when packaging looks intact.

Guidelines For Proper Use

Advice From Canadian Pharmacists

Pharmacists should screen for nitrates, cardiac disease, hepatic and renal impairment and concomitant strong CYP3A4 inhibitors before advising use of any PDE5, including imported udenafil.

Document counselling and advise against unsupervised switching from a DIN product to an imported agent.

Offer clinically appropriate DIN alternatives available at Shoppers, Rexall, Jean Coutu or London Drugs when possible.

Provincial Health Authority Guidance

Provincial authorities require a DIN for formulary coverage under ODB, BC PharmaCare and RAMQ.

Public health messaging is to discourage unsupervised importation, encourage adverse event reporting to MedEffect Canada and to seek prescriber review before starting any non‑DIN PDE5 agent.

Clinical pathway: assess cardiovascular risk, trial an approved PDE5 first and only consider importation with documented informed consent and pharmacist oversight.

Delivery Across Canada (English)

Storage & Transport

Store Zydena below 25°C in the original blister to protect from moisture and direct sunlight.

Avoid leaving tablets in hot cars or damp rooms where degradation can accelerate.

When receiving international parcels, check for intact seals, a lot number and an expiry date as part of a quick visual inspection.

Guidelines For Proper Use

Advice From Canadian Pharmacists

Screen patients for nitrates, cardiac history, hepatic or renal impairment and concurrent CYP3A4 inhibitors as a routine safety step.

Document counselling when a patient intends to use an imported PDE5 product and advise trialling a DIN‑approved alternative first.

Provincial Health Authority Guidance

Provincial formularies require a DIN for listing and reimbursement; advise patients that imported utenafil will not be covered.

Encourage reporting of any suspected adverse reactions from imported products to MedEffect Canada and ensure prescriber follow‑up before continued use.

Final Notes

Udenafil (Zydena) is a PDE5 inhibitor with a moderate onset and a longer reported duration than sildenafil based on regional trials, but it lacks Health Canada approval as of July 2025.

Patients considering udenafil should discuss risks, sources and alternatives with a clinician and pharmacist and prioritise DIN‑approved products when possible.

If an imported product is used, document counselling, monitor closely for adverse effects and report any safety concerns to MedEffect Canada.